Nukkleus Cost Of Revenue vs Capex To Revenue Analysis

NUKKW Stock

0.03 0.00 0.00%

Nukkleus financial indicator trend analysis is infinitely more than just investigating Nukkleus recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nukkleus is a good investment. Please check the relationship between Nukkleus Cost Of Revenue and its Capex To Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nukkleus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Nukkleus Stock please use our How to Invest in Nukkleus guide.

Cost Of Revenue vs Capex To Revenue

Cost Of Revenue vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nukkleus Cost Of Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Nukkleus' Cost Of Revenue and Capex To Revenue is -0.71. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Nukkleus, assuming nothing else is changed. The correlation between historical values of Nukkleus' Cost Of Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Nukkleus are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Cost Of Revenue i.e., Nukkleus' Cost Of Revenue and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.71

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Nukkleus income statement and represents the costs associated with goods and services Nukkleus provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Nukkleus' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nukkleus current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nukkleus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Nukkleus Stock please use our How to Invest in Nukkleus guide.Selling General Administrative is likely to climb to about 3.4 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.19 in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	6.2M	3.2M	3.7M	3.9M
Cost Of Revenue	22.2M	16.3M	18.7M	13.6M

Total Operating Expenses Cost Of Revenue

Nukkleus fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Net Receivables	Non Current Liabilities Total	Other Current Assets	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Short Term Investments	Inventory	Net Invested Capital	Capital Stock	Net Working Capital
Total Assets		0.91	0.95	0.98	0.18	-0.91	0.98	0.89	0.77	-0.29	0.98	0.95	0.9	0.01	0.93	0.48	-0.6	0.66	0.95	-0.89	0.61	0.5	0.51	0.99	0.94	-0.89
Other Current Liab	0.91		0.96	0.84	-0.12	-0.84	0.85	0.81	0.6	-0.59	0.89	0.96	0.93	-0.11	0.82	0.62	-0.66	0.85	0.81	-0.9	0.68	0.33	0.37	0.88	0.83	-0.79
Total Current Liabilities	0.95	0.96		0.88	0.11	-0.92	0.89	0.84	0.74	-0.41	0.94	1.0	0.96	0.03	0.87	0.59	-0.68	0.72	0.87	-0.94	0.62	0.3	0.44	0.92	0.88	-0.88
Total Stockholder Equity	0.98	0.84	0.88		0.19	-0.87	0.99	0.88	0.76	-0.21	0.96	0.87	0.82	-0.02	0.92	0.4	-0.53	0.6	0.96	-0.82	0.58	0.6	0.53	0.99	0.94	-0.85
Net Debt	0.18	-0.12	0.11	0.19		-0.17	0.17	0.11	0.45	0.71	0.13	0.12	0.18	0.72	0.11	0.12	-0.06	-0.36	0.26	-0.22	-0.32	0.24	-0.03	0.17	0.19	-0.18
Retained Earnings	-0.91	-0.84	-0.92	-0.87	-0.17		-0.87	-0.81	-0.79	0.29	-0.96	-0.92	-0.82	0.07	-0.94	-0.26	0.55	-0.51	-0.88	0.78	-0.56	-0.15	-0.72	-0.92	-0.91	1.0
Accounts Payable	0.98	0.85	0.89	0.99	0.17	-0.87		0.86	0.74	-0.23	0.96	0.88	0.81	-0.05	0.92	0.4	-0.52	0.61	0.95	-0.83	0.59	0.58	0.53	0.99	0.93	-0.85
Cash	0.89	0.81	0.84	0.88	0.11	-0.81	0.86		0.86	-0.14	0.88	0.84	0.77	0.16	0.77	0.35	-0.76	0.47	0.85	-0.76	0.55	0.48	0.49	0.89	0.84	-0.78
Cash And Short Term Investments	0.77	0.6	0.74	0.76	0.45	-0.79	0.74	0.86		0.21	0.77	0.74	0.64	0.43	0.64	0.26	-0.78	0.14	0.84	-0.68	0.33	0.38	0.45	0.78	0.82	-0.77
Common Stock Shares Outstanding	-0.29	-0.59	-0.41	-0.21	0.71	0.29	-0.23	-0.14	0.21		-0.31	-0.4	-0.44	0.68	-0.36	-0.35	0.04	-0.83	-0.15	0.35	-0.53	0.21	-0.14	-0.25	-0.22	0.27
Other Stockholder Equity	0.98	0.89	0.94	0.96	0.13	-0.96	0.96	0.88	0.77	-0.31		0.93	0.85	-0.09	0.97	0.33	-0.55	0.61	0.93	-0.82	0.65	0.38	0.66	0.99	0.94	-0.94
Total Liab	0.95	0.96	1.0	0.87	0.12	-0.92	0.88	0.84	0.74	-0.4	0.93		0.96	0.05	0.86	0.58	-0.69	0.72	0.86	-0.93	0.62	0.29	0.44	0.92	0.87	-0.88
Total Current Assets	0.9	0.93	0.96	0.82	0.18	-0.82	0.81	0.77	0.64	-0.44	0.85	0.96		0.12	0.78	0.72	-0.62	0.78	0.81	-0.96	0.55	0.32	0.26	0.85	0.81	-0.78
Common Stock	0.01	-0.11	0.03	-0.02	0.72	0.07	-0.05	0.16	0.43	0.68	-0.09	0.05	0.12		-0.25	0.29	-0.45	-0.35	0.06	-0.17	-0.36	0.28	-0.38	-0.03	-0.01	0.11
Short Long Term Debt Total	0.93	0.82	0.87	0.92	0.11	-0.94	0.92	0.77	0.64	-0.36	0.97	0.86	0.78	-0.25		0.21	-0.35	0.59	0.87	-0.72	0.67	0.27	0.75	0.94	0.9	-0.94
Net Receivables	0.48	0.62	0.59	0.4	0.12	-0.26	0.4	0.35	0.26	-0.35	0.33	0.58	0.72	0.29	0.21		-0.51	0.7	0.4	-0.8	0.15	0.39	-0.45	0.39	0.35	-0.2
Non Current Liabilities Total	-0.6	-0.66	-0.68	-0.53	-0.06	0.55	-0.52	-0.76	-0.78	0.04	-0.55	-0.69	-0.62	-0.45	-0.35	-0.51		-0.31	-0.57	0.67	-0.3	-0.32	-0.09	-0.57	-0.55	0.49
Other Current Assets	0.66	0.85	0.72	0.6	-0.36	-0.51	0.61	0.47	0.14	-0.83	0.61	0.72	0.78	-0.35	0.59	0.7	-0.31		0.54	-0.74	0.6	0.27	0.06	0.61	0.55	-0.47
Non Current Assets Total	0.95	0.81	0.87	0.96	0.26	-0.88	0.95	0.85	0.84	-0.15	0.93	0.86	0.81	0.06	0.87	0.4	-0.57	0.54		-0.83	0.54	0.54	0.5	0.96	0.99	-0.87
Non Currrent Assets Other	-0.89	-0.9	-0.94	-0.82	-0.22	0.78	-0.83	-0.76	-0.68	0.35	-0.82	-0.93	-0.96	-0.17	-0.72	-0.8	0.67	-0.74	-0.83		-0.41	-0.43	-0.15	-0.84	-0.81	0.74
Other Assets	0.61	0.68	0.62	0.58	-0.32	-0.56	0.59	0.55	0.33	-0.53	0.65	0.62	0.55	-0.36	0.67	0.15	-0.3	0.6	0.54	-0.41		0.1	0.53	0.61	0.64	-0.53
Short Term Investments	0.5	0.33	0.3	0.6	0.24	-0.15	0.58	0.48	0.38	0.21	0.38	0.29	0.32	0.28	0.27	0.39	-0.32	0.27	0.54	-0.43	0.1		-0.14	0.51	0.43	-0.12
Inventory	0.51	0.37	0.44	0.53	-0.03	-0.72	0.53	0.49	0.45	-0.14	0.66	0.44	0.26	-0.38	0.75	-0.45	-0.09	0.06	0.5	-0.15	0.53	-0.14		0.58	0.57	-0.76
Net Invested Capital	0.99	0.88	0.92	0.99	0.17	-0.92	0.99	0.89	0.78	-0.25	0.99	0.92	0.85	-0.03	0.94	0.39	-0.57	0.61	0.96	-0.84	0.61	0.51	0.58		0.95	-0.9
Capital Stock	0.94	0.83	0.88	0.94	0.19	-0.91	0.93	0.84	0.82	-0.22	0.94	0.87	0.81	-0.01	0.9	0.35	-0.55	0.55	0.99	-0.81	0.64	0.43	0.57	0.95		-0.9
Net Working Capital	-0.89	-0.79	-0.88	-0.85	-0.18	1.0	-0.85	-0.78	-0.77	0.27	-0.94	-0.88	-0.78	0.11	-0.94	-0.2	0.49	-0.47	-0.87	0.74	-0.53	-0.12	-0.76	-0.9	-0.9

Click cells to compare fundamentals

Nukkleus Account Relationship Matchups

Nukkleus fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	203.0K	3.8M	16.7M	18.4M	21.1M	22.2M
Other Current Liab	5.0M	4.6M	3.6M	7.2M	8.3M	8.7M
Total Current Liabilities	1.3M	5.2M	4.6M	7.5M	8.6M	9.0M
Total Stockholder Equity	(1.3M)	(1.4M)	12.0M	10.9M	12.5M	13.2M
Net Debt	161.0K	1.3M	3.3M	(364.0K)	(418.6K)	(397.7K)
Retained Earnings	(1.5M)	(1.6M)	(2.5M)	(14.3M)	(12.9M)	(12.3M)
Cash	23.5K	82.8K	355.7K	364.0K	418.6K	439.6K
Cash And Short Term Investments	82.9K	355.7K	612.2K	364.0K	418.6K	238.2K
Common Stock Shares Outstanding	6.3M	257.8M	356.1M	10.1M	9.1M	8.6M
Liabilities And Stockholders Equity	203.0K	3.8M	16.7M	18.4M	21.1M	22.2M
Total Liab	1.5M	5.2M	4.6M	7.5M	8.6M	9.0M
Total Current Assets	203.0K	3.8M	3.0M	3.7M	4.2M	4.5M
Short Long Term Debt Total	181.8K	243.8K	1.6M	3.7M	4.2M	4.4M
Net Receivables	3.9K	3.7M	2.7M	966.1K	1.1M	1.3M
Non Current Liabilities Total	246.2K	247.6K	180.5K	254.9K	229.4K	278.9K
Other Current Assets	3.7M	2.6M	89.0K	3.3M	3.8M	4.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Nukkleus Stock Analysis

When running Nukkleus' price analysis, check to measure Nukkleus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nukkleus is operating at the current time. Most of Nukkleus' value examination focuses on studying past and present price action to predict the probability of Nukkleus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nukkleus' price. Additionally, you may evaluate how the addition of Nukkleus to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nukkleus Cost Of Revenue vs Capex To Revenue Analysis

Cost Of Revenue vs Capex To Revenue

Cost Of Revenue vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Capex To Revenue

Nukkleus fundamental ratios Correlations

Nukkleus Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Nukkleus fundamental ratios Accounts

Also Currently Popular

Additional Tools for Nukkleus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Net Working Capital	+ 1.0	Retained Earnings
Net Invested Capital	+ 0.99	Total Assets
Accounts Payable	+ 0.99	Total Stockholder Equity
Net Invested Capital	+ 0.99	Total Stockholder Equity
Net Invested Capital	+ 0.99	Accounts Payable

Non Currrent Assets Other	- 0.96	Total Current Assets
Other Stockholder Equity	- 0.96	Retained Earnings
Net Working Capital	- 0.94	Short Long Term Debt Total
Net Working Capital	- 0.94	Other Stockholder Equity
Short Long Term Debt Total	- 0.94	Retained Earnings
Non Currrent Assets Other	- 0.94	Total Current Liabilities